Results 71 to 80 of about 40,241 (253)

Artificial intelligence and machine learning‐assisted digital applications for biopharmaceutical manufacturing

Biotechnology Progress, EarlyView.
Abstract Artificial intelligence and automation are no longer just buzzwords in the biopharmaceutical industry. The manufacturing of a class of biologics, comprising monoclonal antibodies, cell therapies, and gene therapies, is far more complex than that of traditional small molecule drugs.
Shyam Panjwani, Hao Wei, John Mason
wiley   +1 more source

Emergence of the Biosimilar Sector and Opportunities of Developing Country Suppliers [PDF]

, 2011
As biologic products begin to come off-patent, a market is emerging for biosimilars (also known as biogenerics or follow-on biologics). Firms from emerging countries such as India and China have dominated the production of active ingredients in ...
Huzair, Farah, Kale, Dinar
core  

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

The Status and Emerging Developments in Laboratory Animal Science in Asia since 9th AFLAS Congress (2023) until 10th AFLAS Congress (2025)

Animal Models and Experimental Medicine, EarlyView.
Asian Federation of Laboratory Animal Science Associations (AFLAS)
wiley   +1 more source

Policy Networks and Policy Entrepreneurship in the EU: Explaining Structural Policy Change in Pharmaceutical Innovation Incentives and Health Technology Assessment

European Policy Analysis, EarlyView.
ABSTRACT Policy process research has excelled in explaining structural policy change within national settings, but extensions and applications to the EU level have long proven challenging for scholars. Given that the EU is currently experiencing its longest period of Treaty stability since the 1980s—having evolved into a sui generis political system ...
Vassilis Karokis‐Mavrikos
wiley   +1 more source

Process Improvement for Maximized Therapeutic Innovation Outcome. [PDF]

, 2017
Deconvoluting key biological mechanisms forms the framework for therapeutic discovery. Strategies that enable effective translation of those insights along the development and regulatory path ultimately drive validated clinical application in patients ...
Terzic, Andre, Waldman, Scott A.
core   +2 more sources

Dosing Biologic Drugs for Patients with Obesity: One Size Does NOT Fit All

Arthritis &Rheumatology, Accepted Article.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source

Development of a step‐gradient simulated moving bed process for the polishing of monoclonal antibodies with anion exchange chromatography

Journal of Chemical Technology &Biotechnology, EarlyView.
Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy, Jonas Wege, Anthony Grabski, Romain Dabre, Egbert Müller, Carsten‐René Arlt   +5 more
wiley   +1 more source

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays [PDF]

, 2017
Background: The commercialization of CT-P13, an infliximab (IFX) biosimilar, has the potential to decrease health-related costs and enhance access to biological therapies.
Cláudia Camila Dias, Fernando Magro, Gonczi L, Helena Tavares de Sousa, Isadora Rosa, Joana Afonso, João Carvalho   +6 more
core   +1 more source

Shift From Adalimumab Originator to Biosimilars in Denmark.

JAMA Internal Medicine, 2020
This study describes the nationwide shift from brand-name adalimumab (originator) to adalimumab biosimilars in Denmark and analyzes what a similar shift in the US would look like.
T. Jensen, Seoyoung C. Kim, E. Jimenez‐Solem, Dorthe Bartels, H. R. Christensen, J. Andersen   +5 more
semanticscholar   +1 more source